Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Anaïs Schavgoulidze (1) , Alexis Talbot (2) , Aurore Perrot (1) , Titouan Cazaubiel (3) , Xavier Leleu (4) , Salomon Manier , Laure Buisson , Sabrina Mahéo (1, 5) , Laura Do Souto Ferreira , Luka Pavageau , Cyrille Hulin (3) , Jean-Pierre Marolleau (6, 7) , Laurent Voillat (8) , Karim Belhadj (9) , Marion Divoux (10) , Borhane Slama (11) , Sabine Brechignac (12) , Margaret Macro (13) , Anne Marie Stoppa (14) , Laurence Sanhes (15) , Frederique Orsini Piocelle , Jean Fontan , Marie-Lorraine Chretien , Hélène Demarquette , Mohamad Mohty , Hervé Avet-Loiseau , Jill Corre

1 CRCT - Centre de Recherches en Cancérologie de Toulouse
2 AP-HP - Hopital Saint-Louis [AP-HP]
3 CHU Bordeaux
4 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
5 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
6 CHU Amiens-Picardie
7 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
8 Centre Hospitalier Chalon-sur-Saône William Morey
9 Hôpital Henri Mondor
10 CHU Nancy - Centre Hospitalier Universitaire de Nancy
11 AU - Avignon Université
12 Hôpital Avicenne [AP-HP]
13 CHU Caen
14 IPC - Institut Paoli-Calmettes
15 Centre Hospitalier Saint Jean de Perpignan

Cytogenetics abnormalities (CA) are known to be the preponderant prognostic factor in multiple myeloma (MM). Our team has recently developed a prognostic score based on 6 CA, where del(1p32) appears to be the second worst abnormality after del(17p). The aim of this study was to confirm the adverse impact of 1p32 deletion on newly-diagnosed multiple myeloma (NDMM) patients. Among 2551 NDMM patients, 11% were harboring del(1p32). Their overall survival (OS) was significantly inferior compared to patients without del(1p32) (median OS: 49 months vs. 124 months). Likewise, progression-free survival was significantly shorter. More importantly, biallelic del(1p32) conferred a dramatically poorer prognosis than a monoallelic del(1p32) (median OS: 25 months vs. 60 months). As expected, the OS of del(1p32) patients significantly decreased when this abnormality was associated with other high-risk CA (del(17p), t(4;14) or gain(1q)). In the multivariate analysis, del(1p32) appeared as a negative prognostic factor; after adjustment for age and treatment, the risk of progression was 1.3 times higher among patients harboring del(1p32), and the risk of death was 1.9 times higher. At the dawn of risk-adapted treatment strategies, we have confirmed the adverse impact of del(1p32) in MM and the relevance of its assessment at diagnosis.

Domaines: Médecine humaine et pathologie

Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, et al.. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood, 2022, ⟨10.1182/blood.2022017863⟩. ⟨hal-03859245⟩